Total Tumor Volume on ¹⁸F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with ²²⁵Ac-PSMA-I&T

Background: PSMA-based alpha therapy using ²²⁵Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of ¹⁷⁷Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV) on PSMA PET impacts therap...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lena M. Unterrainer, Leonie Beyer, Mathias J. Zacherl, Franz J. Gildehaus, Andrei Todica, Sophie C. Kunte, Adrien Holzgreve, Gabriel T. Sheikh, Annika Herlemann, Jozefina Casuscelli, Matthias Brendel, Nathalie L. Albert, Vera Wenter, Nina-Sophie Schmidt-Hegemann, Wolfgang G. Kunz, Clemens C. Cyran, Jens Ricke, Christian G. Stief, Peter Bartenstein, Harun Ilhan, Marcus Unterrainer
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2022-04-01
coleção:	Biomedicines
Assuntos:	PSMA PET/CT total tumor volume <sup>225</sup>Ac-PSMA mCRPC
Acesso em linha:	https://www.mdpi.com/2227-9059/10/5/946
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!